China High Quality Azilsartan Medoxomil Factories – 99% Apixaban CAS 503612-47-3 – Baoran

Short Description:

Product Detail

Product Tags

Feedback (2)

We know that we only thrive if we can easily guarantee our combined cost competiveness and high-quality advantageous at the same time for Benzhydrol, Cas 115-83-3, Hydroquinone, At our firm with quality first as our motto, we manufacture products that are entirely made in Japan, from materials procurement to processing. This enables them to be used with confident peace of mind.

China High Quality Azilsartan Medoxomil Factories – 99% Apixaban CAS 503612-47-3 – Baoran Detail:

Specification

ITEM	STANDARD
Appearance	White to off-white solid
Purity	≥ 99%

Application

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a joint development of the new oral anticoagulant apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin.
In May 2011, apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
The Canadian Food and Drug Administration, Japan, and the U.S. Food and Drug Administration subsequently approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, ELIQUIS (Apixaban), was officially announced on the market in China. Apixaban is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its launch provides a safe and effective new option for anticoagulation after orthopaedic surgery in clinical practice, and brings good news to Chinese patients undergoing elective hip/knee replacement.
Clinical studies have confirmed that compared with 40 mg subcutaneous injection of enoxaparin once a day, 2.5 mg of ELIQUIS (Apixaban) orally twice a day is more effective in preventing venous thromboembolic events after hip or knee replacement surgery , and does not increase the risk of bleeding.

Packing & Storage

100g/500g/1kg/25kg or as request;
Stored at room temperature and airtight.

Product detail pictures:

Related Product Guide:

We thinks what clients think, the urgency of urgency to act from the interests of a purchaser position of principle, allowing for greater top quality, decrease processing costs, price ranges are much more reasonable, won the new and aged prospects the support and affirmation for China High Quality Azilsartan Medoxomil Factories – 99% Apixaban CAS 503612-47-3 – Baoran, The product will supply to all over the world, such as: Provence, Auckland, Slovakia, Based on our automatic production line, steady material purchase channel and quick subcontract systems have been built in mainland China to meet customer's wider and higher requirement in recent years. We are looking forward to cooperating with more clients worldwide for common development and mutual benefit!Your trust and approval are the best reward for our efforts. Keeping honest, innovative and efficient, we sincerely expect that we can be business partners to create our brilliant future!

17639-93-9

22483-09-6

Azilsartan Medoxomil

Heparin Lithium

Levamisol Hydrochloride

N,N-Bis(Carboxymethyl)-L-Lysine

Ronidazole

Tetracaine Hydrochloride

Tetramethyl Guanidine

Valerophenone

This is a honest and trustworthy company, technology and equipment are very advanced and the prodduct is very adequate, there is no worry in the suppliment.